These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26285615)

  • 1. Obinutuzumab in chronic lymphocytic leukemia.
    Dupuis J
    Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
    Hoy SM
    Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
    Dawson K; Moran M; Guindon K; Wan H
    Clin J Oncol Nurs; 2016 Apr; 20(2):E41-8. PubMed ID: 26991722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
    Tam C; Kuss B; Opat S; Boulos J; Marlton P
    Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on obinutuzumab in the treatment of B-cell malignancies.
    Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Salvaris R; Opat S
    Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obinutuzumab breaks through to FDA approval.
    Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 18. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
    Chaudhry M; Cheson BD
    Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of obinutuzumab-associated toxicities: Australian experience.
    Snowden A; Hayden I; Dixon J; Gregory G
    Int J Nurs Pract; 2015 Dec; 21 Suppl 3():15-27. PubMed ID: 26681665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab: first global approval.
    Cameron F; McCormack PL
    Drugs; 2014 Jan; 74(1):147-54. PubMed ID: 24338113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.